No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Changzhou Qianhong Biopharma CO.,LTD operates as a key player in China's biopharmaceutical sector, specializing in the research, development, production, and distribution of biological drugs, with a core focus on enzyme and polysaccharide-based compounds. The company's product lineup features a variety of active pharmaceutical ingredients (APIs). These include a range of anticoagulants such as heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium, alongside pancreatin for digestive aid, asparaginase for antineoplastic applications, kallidinogenase kallikrein for treating microcirculation disorders, and heparinoid. Furthermore, Changzhou Qianhong provides ready-to-administer preparations, like pre-filled syringes of nadroparin calcium, enoxaparin sodium, and dalteparin sodium, all used as anticoagulants. It also supplies asparaginase injections for cancer treatment and heparin sodium injections to prevent blood clots. The company extends its reach through the export of its products internationally. Founded in 1971, Changzhou Qianhong Biopharma CO.,LTD maintains its headquarters in Changzhou, China.
www.qhsh.com.cnNo one on the platform currently holds 002550.SZ.
No tracked institution reports a position in 002550.SZ as of their last filing.
No one on the platform has traded 002550.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 16.8% | 13.7% | — | — | — | |
| Rev. Growth % | 3.0% | -1.2% | ||||
| Profit Margin % | 25.4% | 16.5% | 15.3% | |||
| Free Cash Flow Margin % | 14.0% | 12.0% | 8.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.7B | +33.4% | $0.33 | $0.33–$0.33 | — | 1 |
| 2027 | $3.3B | +19.9% | $0.41 | $0.41–$0.41 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.31 | -0.00% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.18 | +0.25% | $9.9B | — |
| 300026.SZTianjin Chase Sun Pharmaceutical Co., Ltd. Class A | $3.18 | -0.00% | $9.6B | — |
| 300119.SZTianjin Ringpu Bio-Technology Co.,Ltd. | $17.46 | +1.33% | $8.1B | — |
| 600129.SSChongqing Taiji Industry(Group) Co.,Ltd | $13.32 | -0.67% | $7.3B | — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. |
Source: Financial Modeling Prep · peers by sector/industry
| $11.37 |
| +0.62% |
| $13.4B |
| — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.07 | -1.04% | $10.8B | — |